CPL207280 + metformin

**CPL207280 + metformin** is an oral combination of two agents with complementary mechanisms targeting type 2 diabetes. **CPL207280** is a novel, orally active G-protein-coupled receptor 40 (GPR40/FFA1) agonist that enhances glucose-stimulated insulin secretion from pancreatic β-cells, offering glucose-lowering effects with low hypoglycemia risk[1][2][3][4][6]. **Metformin** is a widely used oral antidiabetic drug that improves peripheral insulin sensitivity, decreases hepatic glucose production, and reduces intestinal glucose absorption. The combination is designed to maximize glycemic control and β-cell preservation by leveraging the insulinotropic effect of CPL207280 and the insulin-sensitizing effect of metformin, with a low risk of hypoglycemia due to the glucose-dependency of GPR40 agonists[1][5]. Early clinical studies indicate that CPL207280 is safe, well-tolerated, and metabolically compatible with metformin[1][3].